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Abstract
Carbamazepine is a commonly used antiepileptic medication. In
overdoses it can produce various side effects involving neurological,
cardiac, hematological and endocrinal systems. Inappropriate secretion
of Anti Diuretic Hormone (ADH) is a well-known complication of
carbamazepine toxicity. We are reporting an unusual complication in an
adolescent girl with intentional carbamazepine overdose. A sixteen year
old female with carbamazepine ingestion presented to our hospital with
altered sensorium. On admission she was found to have a very high
serum carbamazepine level and metabolic acidosis. In contrast to the
possible inappropriate secretion of ADH, as an adverse effect of
carbamazepine, her hospital course was complicated with a diabetes
insipidus – like condition following treatment with multiple doses of
activated charcoal and sodium bicarbonate therapy.
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Case presentation
A 16-year-old female, with a history of depression, was brought to our
hospital after an intentional overdose of carbamazepine. The patient was
found lying by the side of the bed in an unresponsive state. The patient’s
mother found approximately twenty (200 mg each) carbamazepine pills
missing from her step-brother’s medication bottle. Emergency Medical
Service (EMS) brought the girl to the Emergency Department. Enroute to
the hospital, a dose of diphenhydramine was given for dystonic
posturing.
The carbamazepine level upon admission was 24.1mcg/ml and a
computed tomography (CT) scan of the brain was reported normal.
Electrocardiogram (ECG) showed borderline QRS widening with possible
right bundle branch block. Echocardiogram and cardiac enzymes were
normal. She was started on activated charcoal and received multiple
doses during her hospital stay. Two hours following admission the child
was intubated and placed on a mechanical ventilator for decreased
sensorium. Sodium bicarbonate was added to intravenous fluids to
correct the metabolic acidosis, with a total intravenous fluid (IVF)
sodium content of 190 meq/l, infused at 150ml/hr. Carbamazepine levels
were monitored every six hours and at six hours after admission the level
was 34.5 mcg /ml and decreased to 4.2 mcg /ml within three days. Urine
toxicology screen was negative. On day two of admission, the patient was
polyuric with a urine output of 7ml/kg /hr, with negative fluid balance of
3398 ml over a 12-hour period. The possibility of diabetes insipidus was
considered and work up was sent. Laboratory data showed
hypernatremia (160 mEq /L) and serum hyperosmolality (329 mosm
/kg) with a urine osmolality of 459 mosm /kg and a urine specific gravity
of 1.000. Appropriate fluid therapy with D51/2NS was initiated and
hypernatremia corrected over the next 48 hours and urine output
normalized. The child was discharged from the Pediatric Intensive Care
Unit (PICU) with normal electrolyte and acid-base balance,
cardiovascular and neurologic condition. Although the fluid balance was
positive for the first 24 hours, she never developed hyponatremia. The
lowest sodium concentration during her stay was 141 mEq/L. Serial
laboratory and fluid balance values are presented in figures 1-3.
Discussion
Carbamazepine is a commonly used medication in children with seizure
disorders. The Annual Report of the American Association of Poison
Control Centers’ 2012 data reported a total of 4149 toxic carbamazepine
exposures; of them 2162 were isolated ingestions. Over 30 percent of
these occurred in children under 19 years of age and 1532 patients
received treatment, with one reported death. (1)
Carbamazepine shares structural similarity with tricyclic antidepressants.
After oral ingestion, peak plasma concentrations are reached in 4 to 8
hours; it can be delayed up to 24 hours with ingestion of larger doses. (2)
Carbamazepine toxicity mainly manifests with neurological and cardiac
side effects. (3,4) A life-threatening complication like coma and apnea
usually occurs in children with peak levels greater than 28mcg/ml. (3)
Other rare, but serious adverse reactions include agranulocytosis, bone
marrow suppression, multiorgan hypersensitivity reactions (DRESS –
drug rash with eosinophilia and systemic symptoms). (2) It can also
produce signs and symptoms of anticholinergic toxidrome. (5)
Other uncommon side effects include hyponatremia due to the syndrome
of inappropriate anti diuretic hormone secretion (SIADH) and abnormal
thyroid function. (6,7) SIADH is characterized by hyponatremia, low
serum osmolality and oliguria. (8) SIADH state, due to carbamazepine, is
thought to occur through two mechanisms: by increasing endogenous
antidiuretic hormone (ADH) release and by increasing the aquaporin 2
channel expression, resulting in enhanced sensitivity of renal tubules to
ADH. (9,10) Carbamazepine is used to treat patients with central or
lithium induced diabetes insipidus. (10,11) However, our index patient
developed a transient diabetes insipidus (DI) like condition. High serum
osmolality, polyuria, hypernatremia, and low urine specific gravity
suggest DI but high urine osmolality in our patient negates the diagnosis.
The high amount of sodium in the IVF, as sodium bicarbonate, and
repeated multiple doses of activated charcoal given to our patient,
resulted in hypernatremia. Activated charcoal has sodium benzoate as a
preservative and pulls fluid from the body into the gastrointestinal tract
resulting in hypernatremia, especially with administration of multiple
doses of charcoal. (12)
Conclusion
SIADH is a commonly reported endocrine complication of
carbamazepine toxicity in pediatric patients. To the best of our
knowledge, there is no association between carbamazepine and diabetes
insipidus. Our index case indicates the need for close monitoring of
serum sodium levels in children receiving multiple doses of activated
charcoal.
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Figure 1. Serial Carbamazepine levels.
Figure 2. Sodium levels.
Figure 3. Representing total input & output (mls).
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